Novotech Releases Report on Global Parkinson’s Disease Clinical Trial Landscape
Novotech, the global full-service clinical Contract Research Organization (CRO), announces the release of its report, Parkinson’s Disease: Global Clinical Trial Landscape 2024. This report provides critical insights into the trends, opportunities, and challenges in Parkinson's disease (PD) research, serving as a valuable resource for companies developing treatments for this complex neurodegenerative disorder.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241218606779/en/
Report Highlights
Parkinson’s disease is one of the fastest-growing neurological conditions, with prevalence expected to double by 2030. This report analyzes global clinical trial data, offering biotech and pharmaceutical companies key information to guide clinical development strategies. Key findings include:
- Global Trial Distribution: Review of over 750 PD trials initiated since 2019, with Asia-Pacific leading at 44% of trials. Major regions include China, the U.S., and Europe, reflecting current research priorities.
- Therapeutic Innovation: Overview of emerging approaches, such as gene therapy, deep brain stimulation, and cell-based therapies aimed at modifying disease progression and improving patient outcomes.
- Pipeline Insights: Analysis of 145 preclinical and 64 clinical-stage drug candidates highlights a diverse therapeutic pipeline in various stages of development.
- Regional Recruitment and Trial Duration: Europe shows higher recruitment efficiency, while Asia-Pacific indicates a need for increased trial density, highlighting operational challenges and opportunities across regions.
Understanding PD’s Growing Impact
The report also explores genetic, epidemiological, and socioeconomic factors influencing PD’s global burden. These insights are essential for companies looking to design targeted, region-specific clinical trials that consider varying patient needs and regulatory requirements.
This report serves as a practical resource for the PD research community, providing actionable insights to support efficient, effective clinical trials.
Gain a comprehensive understanding of the Parkinson’s disease clinical trial landscape and access actionable insights to support your development goals. Download the full report to inform your strategies in PD research and clinical trials.
About NovotechNovotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Frost &Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena Excellence Awards 2024, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241218606779/en/
Contacts
Media Contact
Toyna Chin
mediacontact@novotech-cro.com
USA: +1 415 364 8135
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brightcove Drives Global Customer Growth and Value Through Strategic Partnerships with Leading MarTech Solutions18.12.2024 18:09:00 EET | Press release
Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, is sharing significant enhancements to its platform through strategic partnerships to enhance the video content creation, distribution and monetization process. As part of the goal to help customers build more cohesive, easy-to-deploy martech stacks, Brightcove has integrated capabilities from companies like Acquia that deliver additional benefits to customers. “As we build strategic partnerships with key providers, we continually look at ways to help our customers reach their business goals. With the right partners, we enable marketers to fully leverage their content and get the most value out of it,” said David Beck, Chief Operating Officer at Brightcove. “Integrating our partners’ strengths – like Acquia’s DAM capabilities – seamlessly into Brightcove’s platform makes it easier for our customers to capture, deploy, and measure video to deliver compelling content that drives engagement and business with
GC Aesthetics® Announces Decade-Long Clinical Evaluation of PERLE™ Breast Implants18.12.2024 17:56:00 EET | Press release
GC Aesthetics® (GCA), a privately-held medical technology company providing aesthetic and reconstruction solutions for global healthcare markets, is proud to announce the initiation of a significant multi-center and prospective clinical study in Europe to evaluate, and confirm, the safety, effectiveness, and patient satisfaction associated with the innovative PERLE™ smooth opaque round breast implant. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241218630395/en/ GC Aesthetics' PERLE™ Breast Implant features a proprietary surface technology (BioQ™) and GCA’s industry-leading gel technology (Emunomic™ Breast Tissue Dynamic Gel). (Photo: Business Wire) This extensive study brings together leading surgeons from the NHS and private clinics in the UK, as well as from private practices across Europe, ensuring a robust and diverse dataset that addresses both cosmetic and reconstructive indications. “By generating high-quality clin
Andersen Global Expands Capabilities with Addition of Valora18.12.2024 16:30:00 EET | Press release
Andersen Global continues to broaden its service offerings through a Collaboration Agreement with Valora, an independent firm specializing in providing custom solutions for both private and institutional clients globally. Valora operates with offices in Miami and Raleigh, along with a global presence in the Dominican Republic, U.K., and Cayman Islands. Founded in 2011 by Partner Luis de Leon, Valora offers a comprehensive range of services, including valuation, performance, accounting and administration, global entity management, fund services, and other tailored solutions. “Collaborating with Andersen is an excellent fit for both our clients and our team,” said Luis. “The synergies within our service offerings will enable us to deliver comprehensive, integrated solutions with ever-increasing global reach.” Global Chairman and CEO of Andersen Mark L. Vorsatz stated, “Valora’s team and culture, along with their practice focus, are well aligned with our organization as we continue to exp
Novotech Publishes Report on the Global COVID-19 Clinical Trial Landscape, Highlighting Key Trends, Therapeutic Advancements, and Challenges in Drug Development18.12.2024 15:05:00 EET | Press release
Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics, has released an in-depth report "COVID-19: Global Clinical Trial Landscape 2024." This report delivers a robust analysis of ongoing and completed COVID-19 clinical trials, therapeutic strategies, and funding trends, offering essential insights for researchers and biotech leaders in the evolving COVID-19 research landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241218899045/en/ The COVID-19 pandemic has led to significant advancements in clinical research and therapeutic innovation. Novotech’s report offers an authoritative analysis of global trial distribution, patient recruitment trends, and emerging therapeutic strategies, drawing on over 5,000 clinical trials conducted since 2019 across Asia-Pacific, North America, Europe, and beyond
ClinChoice Extends 13-Year Medidata Partnership with the Addition of Clinical Data Studio to Improve Data Management and Strengthen Clinical Trial Capabilities18.12.2024 15:00:00 EET | Press release
Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, has renewed its long-standing enterprise partnership with ClinChoice, a global contract research organization (CRO). Under this new agreement, ClinChoice will utilize the Medidata Platform to streamline study data and supply management, boost trial efficiency, and accelerate growth as a full-service CRO in Asia, Europe, and North America. ClinChoice also plans to prioritize Clinical Data Studio accreditation, further enhancing its capabilities through a transformative AI-powered data quality management experience. ClinChoice’s commitment in utilizing Medidata’s solution has spanned over a decade, facilitating secure connections among patients, sites, and sponsors within a unified cloud environment. As an early adopter, ClinChoice played a critical role during the pandemic by deploying Rave RTSM’s Direct-to-Patient model, which maintained patient access and optimized inven
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom